These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12670397)

  • 21. PTEN: life as a tumor suppressor.
    Simpson L; Parsons R
    Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
    Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
    Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of the PTEN phosphatase.
    Gericke A; Munson M; Ross AH
    Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases.
    Eramo MJ; Mitchell CA
    Biochem Soc Trans; 2016 Feb; 44(1):240-52. PubMed ID: 26862211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
    Steelman LS; Bertrand FE; McCubrey JA
    Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
    Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA
    J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.
    Besson A; Robbins SM; Yong VW
    Eur J Biochem; 1999 Aug; 263(3):605-11. PubMed ID: 10469123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic switching of PI3K-dependent lipid signals.
    Downes CP; Leslie NR; Batty IH; van der Kaay J
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):188-92. PubMed ID: 17371235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN.
    Mandl A; Sarkes D; Carricaburu V; Jung V; Rameh L
    Mol Cell Biol; 2007 Dec; 27(23):8098-112. PubMed ID: 17893321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoinositide phosphatases: just as important as the kinases.
    Dyson JM; Fedele CG; Davies EM; Becanovic J; Mitchell CA
    Subcell Biochem; 2012; 58():215-79. PubMed ID: 22403078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTEN: The down side of PI 3-kinase signalling.
    Leslie NR; Downes CP
    Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphoinositide signaling disorders in human diseases.
    Pendaries C; Tronchère H; Plantavid M; Payrastre B
    FEBS Lett; 2003 Jul; 546(1):25-31. PubMed ID: 12829232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells.
    Xu Z; Stokoe D; Kane LP; Weiss A
    Cell Growth Differ; 2002 Jul; 13(7):285-96. PubMed ID: 12133897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of phosphoinositide signaling by the inositol polyphosphate 5-phosphatases.
    Astle MV; Seaton G; Davies EM; Fedele CG; Rahman P; Arsala L; Mitchell CA
    IUBMB Life; 2006 Aug; 58(8):451-6. PubMed ID: 16916781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatases as small-molecule targets: inhibiting the endogenous inhibitors of kinases.
    Schmid AC; Woscholski R
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):348-9. PubMed ID: 15046606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal PTEN expression in portal hypertensive gastric mucosa: a key to impaired PI 3-kinase/Akt activation and delayed injury healing?
    Tsugawa K; Jones MK; Akahoshi T; Moon WS; Maehara Y; Hashizume M; Sarfeh IJ; Tarnawski AS
    FASEB J; 2003 Dec; 17(15):2316-8. PubMed ID: 14525948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.
    Weng LP; Brown JL; Baker KM; Ostrowski MC; Eng C
    Hum Mol Genet; 2002 Jul; 11(15):1687-96. PubMed ID: 12095911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B.
    Lizcano JM; Alrubaie S; Kieloch A; Deak M; Leevers SJ; Alessi DR
    Biochem J; 2003 Sep; 374(Pt 2):297-306. PubMed ID: 12841848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.